News
A new early phase contract development and manufacturing organization (CDMO), Ardena, has launched following the merging of Pharmavize and Crystallics. The two companies came together in 2016 with backing from investor Mentha Capital. The new brand name, Ardena, reveals the increased service offering and complementary capabilities of Pharmavize in Belgium and Crystallics in the Netherlands. […]
more >
Alexion Pharmaceuticals announced an operational plan to re-align the global organization with its refocused corporate strategy. The plan is expected to deliver approximately $270 million in GAAP and approximately $250 million in non-GAAP pre-tax savings annually by 2019. The restructuring will reduce the company’s global workforce by approximately 20%. The resulting savings will allow Alexion […]
more >
ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of institutional and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders. Amylon […]
more >
National Library of Medicine (NLM) Director Patricia Flatley Brennan, R.N., Ph.D., has appointed James M. Ostell, Ph.D., as the director of the National Center for Biotechnology Information (NCBI), a division of NLM at the NIH. Dr. Ostell has been with NCBI since it was established by Congress in 1988, and has helped shape it into one […]
more >
Certara, a provider of model-informed drug development and regulatory science, announced that Kyowa Hakko Kirin has joined the Simcyp Consortium and licensed the Simcyp Population-based Simulator. Kyowa Hakko Kirin is the 36th leading biopharmaceutical company and the 11th Japanese pharmaceutical company to join the Consortium. Member companies meet in a pre-competitive environment and work together to […]
more >
Novartis gets FDA approval for first-ever CAR-T cancer therapy; other applications on the horizon The emerging field of modifying and deploying a patient’s own cells to fight cancer just got some big legs under it with the late August approval of a new treatment for pediatric and young adult leukemia. The therapy, known as chimeric […]
more >
